Overview

* Larimar reports Q3 net loss of $47.7 mln, driven by increased R&D expenses

* Company modifies nomlabofusp dosing to reduce anaphylaxis risk

* BLA submission for nomlabofusp targeted for Q2 2026

Outlook

* Larimar targets BLA submission for nomlabofusp in Q2 2026

* Company plans U.S. launch of nomlabofusp in early 2027

* Larimar implementing modified dosing regimen to reduce anaphylaxis risk

Result Drivers

* Research and development expenses for the third quarter of 2025 were $44.9 million compared to $13.9 million for the third quarter of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.61

Q3 Net -$47.71

Income mln

Q3 Basic -$0.61

EPS

Q3 -$49.49

Income mln

From

Operatio

ns

Q3 $49.49

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Larimar Therapeutics Inc ( LRMR ) is $17.00, about 77.6% above its November 4 closing price of $3.80

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)